MiRNA-200a sensitizes non-small-cell lung cancer to EGFR-TKIs by targeting FOXC1
CSTR:
Author:
Affiliation:

Clc Number:

Fund Project:

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    Objective: To investigate the role of miRNA-200a in the efficacy of targeted therapy in non-small-cell lung cancer (NSCLC) patients and its underlying mechanisms. Methods: Real-time polymerase chain reaction and Western blot were used to investigate the level of miRNA-200a and FOXC1. The MTT assay,wound-healing and Transwell assays were performed to measure the effect of miRNA-200a and FOXC1 on cell growth, migration, invasion and other biological behaviors. Luciferase reporter assay analyzed the relationship between FOXC1 and miRNA-200a. Results: We found that a high level of miRNA-200a inhibited NSCLC cells growth, EMT, migration and invasion and increased sensitivity to gefitinib by targeting FOXC1. Furthermore, suppression of FOXC1 also inhibits cells progression and restores gefitinib resistance. Conclusion: Upregulated miRNA-200a or knockdown of FOXC1 enhanced sensitivity to gefitinib in NSCLCs. This may provide a novel effective therapeutic approach to overcome the acquisition of resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy.

    Reference
    Related
    Cited by
Get Citation

尹 媛,许 伟,吴双双,李 燕,赵卫红,吴剑卿. miRNA-200a调控FOXC1增敏肺癌EGFR-TKI治疗的研究[J].南京医科大学学报(自然科学版英文版),2017,(9):1067-1075.

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:April 03,2017
  • Revised:
  • Adopted:
  • Online: September 25,2017
  • Published:
Article QR Code